Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. Once developed, the ADCs will join BioNTech’s existing portfolio of oncology products.

Development 246

Development Sales Antibody Manufacturing 246

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). As per the terms of the agreement, LegoChem will receive up to $1.25bn in upfront, development and commercial milestone payments from Amgen.

Antibody 130

Antibody Development Drugs Licensing 130

pharmaphorum

APRIL 27, 2022

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding £1.3 billion with no sales recorded in the prior year.

Sales 97

Sales Antibody Vaccine Vaccination 97

Pharmaceutical Technology

NOVEMBER 27, 2022

Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.

Antibody 130

Antibody Licensing Licensing Development 130

Pharmaceutical Technology

MAY 30, 2023

Lecanemab by Eisai Co Ltd, a monoclonal antibody therapy marketed for Alzheimer’s disease, is predicted to achieve the most significant commercial debut. Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda. Similarly, Almirall S.A.,

Drugs 264

Drugs Sales Antibody Dermatology 264

Pharmaceutical Technology

APRIL 3, 2023

Innate Pharma has signed an exclusive licence agreement with Takeda to enable research and development of antibody drug conjugates (ADCs) against an undisclosed target, primarily focusing on coeliac disease. In addition, Innate will receive royalties on possible net sales of any commercial product to be developed under the licence.

Development 130

Development Antibody Pharma Production Engineer 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Pharmaceutical Technology

DECEMBER 19, 2022

With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

Pharmaceutical Technology

SEPTEMBER 15, 2022

As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.

Vaccine 272

Vaccine Vaccination Sales Generic Drugs 272

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Pharmaceutical Technology

OCTOBER 7, 2022

Surrozen and Boehringer Ingelheim have entered a partnership and licence agreement for researching and developing SZN-413 to treat retinal diseases. on meeting development, regulatory and commercial milestones, apart from sales-based royalty payments. A bi-specific antibody, SZN-413 acts on Fzd4-mediated Wnt signalling.

Development 147

Development Genetics Sales Antibody 147

Pharmaceutical Technology

JANUARY 6, 2023

Dutch biotechnology company Synaffix and Amgen have entered a licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Additionally, the company will be eligible to receive tiered royalties on commercial sales of the products. This is Synaffix’s 12th licensing agreement to date.

Development 130

Development Licensing Licensing Antibody 130

Pharmaceutical Technology

DECEMBER 23, 2022

Merck (MSD outside North America) has signed an exclusive licence and partnership agreement with Kelun-Biotech for developing seven investigational preclinical antibody-drug conjugates (ADC) to treat cancer. Kelun-Biotech is entitled to get payments of up to $9.3bn in the future on meeting development, regulatory and sales milestones.

Development 130

Development Sales Production Antibody 130

pharmaphorum

OCTOBER 20, 2021

High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche’s diagnostics division, allowing the company to raise its sales forecast for the year. Diagnostics sales rose 39% to CHF 13.3 Group sales rose 8% to CHF 46.7 Group sales rose 8% to CHF 46.7 billion ($14.4

Sales 98

Sales Antibody Vaccine Vaccination 98

Pharmaceutical Technology

NOVEMBER 18, 2022

Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. Under the deal, the companies will work together on the discovery activities for identifying and validating the conditionally active bispecific antibodies.

Development 130

Development Antibody Licensing Licensing 130

pharmaphorum

NOVEMBER 8, 2021

A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data. The post One dose of Regeneron’s COVID antibody protects for eight months appeared first on. That was down from almost $2.6

Antibody 105

Antibody Vaccine Vaccination Immune Response 105

pharmaphorum

OCTOBER 25, 2021

Novartis isn’t giving up on the programme yet, as it still has other trials of canakinumab in play, but the latest failure makes prospects for the antibody in oncology look increasingly remote. The post Strike two for Novartis’ lung cancer antibody canakinumab appeared first on.

Antibody 124

Antibody Trials Branding Protein 124

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. Last year, sales at the JV stabilised at £9.6 billion but have been.

Sales 105

Sales Production Vaccine Vaccination 105

Pharmaceutical Technology

MAY 8, 2023

Shanghai Junshi Biosciences and Dr. Reddy’s Laboratories have partnered for the development and commercialisation of the anti-PD-1 monoclonal antibody, toripalimab, in 21 countries. Junshi Biosciences may get an aggregate of up to $728.3m

Development 130

Development Marketing Licensing Licensing 130

Pharmaceutical Technology

AUGUST 18, 2022

Atomwise is also eligible to receive additional research, development and sales-based milestone payments totalling to over $1bn. Furthermore, Sanofi will make tiered royalty payments on products that are developed under this partnership. These targets will be exclusive to Sanofi.

Drugs 246

Drugs Engineer Medicine Sales 246

Pharmaceutical Technology

AUGUST 16, 2022

Q32 Bio has signed a partnership and option agreement with Horizon Therapeutics for developing ADX-914 to treat autoimmune ailments. According to the deal, Horizon will provide the funding to develop the therapy until the conclusion of its two Phase II clinical trials. Q32 will also receive tiered royalty payments on net sales.

Development 130

Development Clinical Trials Clinical Trials Regulation 130

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). We look forward to working with Ono Pharmaceutical to accelerate treatments across a variety of diseases.”.

Research 130

Research Antibody Sales Development 130

Pharmaceutical Technology

OCTOBER 5, 2022

miRecule and Sanofi have entered a strategic partnership and exclusive licence agreement for the development and commercialisation of an antibody-RNA conjugate (ARC) to treat facioscapulohumeral muscular dystrophy (FSHD). Sanofi will exclusively develop and commercialise the drug candidate.

Development 130

Development RNA Gene Therapy Sales 130

World of DTC Marketing

APRIL 11, 2021

QUICK THOUGHT: People believe the COVID-19 vaccine was developed in less than a year but that’s not true. Does this explain the development of the vaccine so rapidly? If your body develops an immune response—the goal of vaccination—there is a possibility you may test positive on some antibody tests.

Vaccine 303

Vaccine Vaccination Clinical Trials Clinical Trials 303

Pharmaceutical Technology

JULY 8, 2022

Swedish Orphan Biovitrum AB (Sobi) has signed an exclusive licence agreement with ADC Therapeutics to develop and market Zynlonta (loncastuximab tesirine) for hematologic and solid tumour indications in Europe and mostinternational markets, for up to $435m. Zynlonta is a CD19-directed antibody-drug conjugate (ADC).

Sales 162

Sales Antibody Marketing Drugs 162

Pharmaceutical Technology

FEBRUARY 8, 2023

Despite receding sales, Comirnaty, its partnered COVID-19 vaccine with BioNTech, is still forecast to reach the analyst consensus global forecast sales of $33 billion for 2022, according to GlobalData’s Drugs Database Pharma Intelligence Center. billion on Dec 31, 2022. Merck & Co. billion to $281.3 and 31.6%, respectively.

Marketing 195

Marketing Sales Vaccine Vaccination 195

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions.

Sales 100

Sales Vaccine Vaccination Drugs 100

XTalks

JANUARY 3, 2025

In this blog, we delve into the recent sales data to highlight the top three best-selling eye drugs in 2023. Lets take a closer look at Eylea, Vabysmo and Lucentis the ophthalmology drugs that led the pack in recent sales figures. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1. billion, down from $1.50

Sales 85

Sales FDA Approval Drugs Medicine 85

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Developed by Sanofi and Regeneron, Praluent was approved by the FDA in July 2015. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Amgen’s Repatha was greenlit a month later.

Antibody 262

Antibody Drugs Protein Sales 262

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies. PD1, BCMA and PDL1 follow as the most common targets.

Marketing 264

Marketing Vaccine Vaccination Development 264

Pharmaceutical Technology

NOVEMBER 21, 2022

Nona Biosciences and Dragonfly Therapeutics have signed a partnership agreement to discover and develop heavy chain only antibody (HCAb)-based drugs. As per the partnership, Nona will offer Dragonfly access to its HCAb technologies and antibody generation services for the targets chosen by the latter.

Antibody 130

Antibody Drugs Engineer Sales 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Cullinan Oncology has signed an exclusive licence with Harbour BioMed for clinical-stage B7H4 x 4-1BB bispecific immune activator HBM7008’s (CLN-418) development and marketing in the US. HBM7008 has been developed from HBICE, a next-generation heavy chain-only antibody (HCAb)-based multi-specific antibody discovery platform.

Antibody 130

Antibody Sales Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. ATV: Aβ uses Denali’s ATV technology to cross the blood-brain barrier (BBB) and increase brain exposure to antibodies.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Pharmaceutical Technology

MAY 12, 2023

On 8 May 2023, China-based Bliss Biopharmaceutical (BlissBio) announced a clinical trial collaboration with Eisai to develop BB-1701, an antibody-drug conjugate (ADC) for multiple cancer types. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.

Clinical Trials 162

Clinical Trials Clinical Trials Licensing Licensing 162

Pharmaceutical Technology

MAY 19, 2023

Roche’s anti-CD20 monoclonal antibody Rituxan/MabThera (rituximab) is one of the most successful oncology drugs of all time. Rituxan received its first FDA approval in 1997 for the treatment of B-cell non-Hodgkin’s lymphoma (B-NHL) and reached peak global sales of $7.5bn in 2014.

Sales 147

Sales Production Marketing FDA Approval 147

Pharmaceutical Technology

SEPTEMBER 2, 2022

lenalidomide) + a steroid ± an anti-CD38 antibody. Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. Should CAR-T cells, or antibodies be used first? Does Blenrep have an efficacy advantage over Tecvayli?

Antibody 147

Antibody Sales FDA Approval Production 147

Pharmaceutical Technology

JANUARY 9, 2023

AbbVie has entered a global collaboration and option agreement with Immunome to discover new antibody-target pairs for cancer treatment. The multi-year collaboration will use Immunome’s Discovery Engine to discover up to ten new antibody pairs arising from three specified types of tumours.

Engineer 130

Engineer Antibody Drugs Immune Response 130